Sangamo Therapeutics analyst ratings
Sangamo Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/13/2022 | 48.15% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 462.96% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 551.85% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 374.07% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 640.74% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 492.59% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 551.85% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 314.81% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 225.93% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 225.93% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 06/20/2018 | 611.11% | B of A Securities | → $24 | Initiates Coverage On | → Buy |
| 11/22/2017 | 492.59% | Barclays | → $20 | Initiates Coverage On | → Overweight |
| 11/15/2017 | — | Piper Sandler | Upgrades | Neutral → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 06/13/2022 | 48.15% | 韦德布什 | → $5 | 假设 | →中性 |
| 04/05/2022 | 462.96% | Truist证券 | $23 → $19 | 维护 | 买 |
| 05/04/2021 | 551.85% | 加拿大皇家银行资本 | → $22 | 开始承保 | →跑赢大盘 |
| 01/06/2021 | 374.07% | Stifel | → $16 | 开始承保 | →保留 |
| 12/16/2020 | 640.74% | HC Wainwright公司 | → $25 | 假设 | →购买 |
| 09/08/2020 | 492.59% | B of A证券 | → $20 | 恢复 | →购买 |
| 07/07/2020 | 551.85% | SunTrust Robinson Humphrey | → $22 | 开始承保 | →购买 |
| 06/22/2020 | 314.81% | HC Wainwright公司 | $16 → $14 | 维护 | 买 |
| 11/14/2018 | 225.93% | 摩根大通 | $35 → $11 | 维护 | 中性 |
| 11/14/2018 | 225.93% | 摩根大通 | $35 → $11 | 评级下调 | 超重→中性 |
| 11/09/2018 | — | 古根海姆 | 评级下调 | 购买→中性 | |
| 06/20/2018 | 611.11% | B of A证券 | → $24 | 开始承保 | →购买 |
| 11/22/2017 | 492.59% | 巴克莱 | → $20 | 开始承保 | →超重 |
| 11/15/2017 | — | 派珀·桑德勒 | 升级 | 中性→超重 |
Sangamo Therapeutics Questions & Answers
Sangamo治疗公司问答
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by Wedbush on June 13, 2022. The analyst firm set a price target for $5.00 expecting SGMO to rise to within 12 months (a possible 48.15% upside). 2 analyst firms have reported ratings in the last year.
韦德布什于2022年6月13日报道了Sangamo治疗公司(纳斯达克：SGMO)的最新目标价。这家分析公司将目标价定为5.00美元，预计SGMO将在12个月内上涨(可能上涨48.15%)。去年有两家分析公司公布了评级。
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by Wedbush, and Sangamo Therapeutics their neutral rating.
韦德布什公司对Sangamo治疗公司(纳斯达克代码：SGMO)的最新分析师评级，Sangamo治疗公司的中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on June 13, 2022 so you should expect the next rating to be made available sometime around June 13, 2023.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Sangamo治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Sangamo治疗公司的上一次评级是在2022年6月13日提交的，所以你应该预计下一次评级将在2023年6月13日左右的某个时候提供。
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a with a price target of $0.00 to $5.00. The current price Sangamo Therapeutics (SGMO) is trading at is $3.38, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Sangamo治疗(SGMO)评级为A，目标价在0.00美元至5.00美元之间。Sangamo治疗公司(SGMO)目前的交易价格为3.38美元，在分析师的预测范围内。
译文内容由第三方软件翻译。